Product Description
Simnova Biotechnology is developing CART-BCMA as a treatment for multiple myeloma. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05346198)
Mechanisms of Action: CAR-T,BCMA
Novel Mechanism: No
Modality: CAR-T
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Synchroneuron
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Multiple Myeloma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| B03B00301-101 | P1 |
Active, not recruiting |
Multiple Myeloma |
2022-07-31 |
13% |
2024-02-24 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| CTR20201885 | P1 |
Active, not recruiting |
Multiple Myeloma |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |